Artelo Biosciences closes $3 million public offering

Artelo Biosciences Inc. (NASDAQ: ARTL) completed a public offering that raised approximately $3.0 million in gross proceeds before underwriting discounts and other expenses.

The clinical-stage pharmaceutical company sold 640,924 shares of common stock at $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at $4.399 per warrant. The pre-funded warrant price represents the public offering price minus the $0.001 exercise price per warrant.

R.F. Lafferty & Co. served as the sole book-running manager and underwriter for the offering. The company granted underwriters a 45-day option to purchase up to 102,272 additional shares at the public offering price to cover over-allotments.

The securities were offered under a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on July 6, 2023, and became effective on July 14, 2023. The final prospectus supplement was filed with the SEC on September 5, 2025.

Artelo develops treatments that target lipid-signaling pathways for conditions including cancer, pain, dermatologic disorders and neurological conditions. The company is based in Solana Beach, California.

You May Also Be Interested In

• DEFSEC Technologies (DFSC) files for 4.05M share offering by selling stockholders
• Genworth Financial adds $500M to share repurchase program
• Greenland Mines closes Sarfartoq rare earth acquisition in Greenland